ABSTRACT
We reported previously that KNT-127 and SNC80, selective agonists of the δ-opioid receptor (DOP), had potent anxiolytic-like effects in rodents. In this study, we evaluated whether KNT-127 and SNC80 influence extinction learning of contextual fear memory in the mice fear conditioning test. On day 1, the mice were contextually conditioned with eight trials (footshock; 0.8â¯mA, 1-s, 30-s interval). On day 2, the mice were re-exposed to the conditioning chamber for 6â¯min as an extinction training (re-exposure 1), 30â¯min after drug administration. On day 3, the mice were re-exposed to the chamber for 6â¯min as a memory testing (re-exposure 2). In re-exposure 1, KNT-127 and SNC80 significantly reduced the freezing behavior. In re-exposure 2, KNT-127, but not SNC80, significantly reduced the freezing behavior. These effects of KNT-127 were antagonized by the DOP antagonist naltrindole. KNT-127 increased the phosphorylated ERK levels in the amygdala and hippocampus, but not in the medial prefrontal cortex 60â¯min after re-exposure 1. These results suggest that both KNT-127 and SNC80 produced anxiolytic-like effects in the re-exposure 1, however, in contrast to SNC80, KNT-127 facilitated extinction learning of contextual fear memory in the re-exposure 2. Further, we suggest that amygdaloid and hippocampal MAPK/ERK signaling serves as the key mediators of the enhancement of extinction learning of contextual fear memory via DOPs after KNT-127 treatment. We propose that, although the DOP agonists KNT-127 and SNC80 produce anxiolytic-like effects on contextually conditioned fear, these drugs have different mechanisms on extinction learning of contextual fear memory.
Subject(s)
Benzamides/pharmacology , Extinction, Psychological/drug effects , Fear/drug effects , Memory/drug effects , Morphinans/pharmacology , Piperazines/pharmacology , Receptors, Opioid, delta/agonists , Animals , Anti-Anxiety Agents/pharmacology , Anxiety/drug therapy , Behavior, Animal/drug effects , Benzamides/administration & dosage , Conditioning, Psychological/drug effects , Learning/drug effects , Male , Mice , Morphinans/administration & dosage , Motor Activity/drug effects , Naltrexone/analogs & derivatives , Naltrexone/antagonists & inhibitors , Piperazines/administration & dosage , Receptors, Opioid, delta/metabolismABSTRACT
Fentanyl is an agonist of the µ-opioid receptor commonly used in the treatment of moderate-severe pain. In order to study whether pharmacogenetics explains some of the variability in the response to fentanyl, several genes related to fentanyl receptors, transporters and metabolic enzymes have been analysed. Thirty-five healthy volunteers (19 men and 16 women) receiving a single 300 µg oral dose of fentanyl were genotyped for 9 polymorphisms in cytochrome P450 (CYP) enzymes (CYP3A4 and CYP3A5), ATP-binding cassette subfamily B member 1 (ABCB1), opioid receptor mu 1 (OPRM1), catechol-O-methyltransferase (COMT) and adrenoceptor beta 2 (ADRB2) by real-time PCR. Fentanyl concentrations were measured by ultra-performance liquid chromatography combined with tandem mass spectrometry (UPLC-MS/MS). Fentanyl pharmacokinetics is affected by sex. Carriers of the CYP3A4*22 allele, which is known to reduce the mRNA expression, showed higher area under the concentration-time curve (AUC) and lower clearance (Cl) values. Although this finding might be of importance, its validity needs to be confirmed in other similar settings. Furthermore, carriers of the ABCB1 C1236T T/T genotype presented a lower AUC and higher Cl, as well as lower half-life (T1/2 ). As volunteers were blocked with naltrexone, the effect of fentanyl on pharmacodynamics might be biased; however, we could observe that fentanyl had a hypotensive effect. Moreover, ADRB2 C523A A allele carriers showed a tendency towards reducing systolic blood pressure. Likewise, OPRM1 and COMT minor allele variants were risk factors for the development of somnolence. CYP3A5*3, ABCB1 C3435T and ABCB1 G2677T/A were not associated with fentanyl's pharmacokinetics, pharmacodynamics and safety profile.
Subject(s)
Fentanyl/pharmacology , Fentanyl/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B/genetics , ATP Binding Cassette Transporter, Subfamily B/metabolism , Adolescent , Adult , Analgesics, Opioid/adverse effects , Analgesics, Opioid/blood , Analgesics, Opioid/pharmacokinetics , Analgesics, Opioid/pharmacology , Catechol O-Methyltransferase/genetics , Catechol O-Methyltransferase/metabolism , Cross-Over Studies , Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/metabolism , Female , Fentanyl/adverse effects , Fentanyl/blood , Gene Frequency , Genotype , Humans , Male , Middle Aged , Naltrexone/antagonists & inhibitors , Pharmacogenetics , Polymorphism, Genetic , Receptors, Adrenergic, beta-1/genetics , Receptors, Adrenergic, beta-1/metabolism , Receptors, Opioid, mu/genetics , Receptors, Opioid, mu/metabolism , Young AdultABSTRACT
Naltrexone is a clinically approved medication for alcoholism. We aimed to investigate the effectiveness of naltrexone co-administered with cocaine and the association of these substances with immediate-early gene expression in the rat prefrontal cortex. We used chronic operant ethanol self-administration and oral treatments prescribed for alcoholism and available in pharmacies to maximise the predictive validity in humans. We performed real-time PCR analysis to determine gene expression levels in the prefrontal cortex. Only the highest dose of naltrexone (1, 3, and 10 mg/kg, p.o.) reduced the response to ethanol. Cocaine increased ethanol self-administration in a dose-dependent manner (2.5, 10, 20 mg/kg, i.p.) and reversed the naltrexone-induced reduction. Naltrexone failed to prevent the cocaine-induced increase in locomotor activity observed in these animals. Chronic self-administration of ethanol reduced the expression of the C-fos gene 4- to 12-fold and increased expression of the COX-2 (up to 4-fold) and Homer1a genes in the rat prefrontal cortex. Chronic ethanol self-administration is prevented by naltrexone, but cocaine fully reverses this effect. This result suggests that cocaine may overcome naltrexone's effectiveness as a treatment for alcoholism. The ethanol-induced reduction in C-fos gene expression in the prefrontal cortex reveals an abnormal activity of these neurons, which may be relevant in the compulsive consumption of ethanol, the control of reward-related areas and the behavioural phenotype of ethanol addiction.
Subject(s)
Alcohol Drinking/genetics , Alcohol Drinking/psychology , Cocaine/pharmacology , Genes, Immediate-Early/genetics , Naltrexone/antagonists & inhibitors , Narcotic Antagonists/pharmacology , Prefrontal Cortex/metabolism , Acamprosate , Alcohol Deterrents/pharmacology , Animals , Carrier Proteins/genetics , Conditioning, Operant/drug effects , Cyclooxygenase 2/genetics , Dose-Response Relationship, Drug , Gene Expression/drug effects , Genes, fos/drug effects , Homer Scaffolding Proteins , Male , Motor Activity , Naltrexone/pharmacology , Rats , Rats, Wistar , Real-Time Polymerase Chain Reaction , Self Administration , Taurine/analogs & derivatives , Taurine/pharmacologyABSTRACT
Opiates such as morphine and fentanyl, a major class of analgesics used in the clinical management of pain, exert their effects through the activation of opioid receptors. Opioids are among the most commonly prescribed and frequently abused drugs in the USA; however, the prolonged use of opiates often leads to the development of tolerance and addiction. Although blockade of opioid receptors with antagonists such as naltrexone and naloxone can lessen addictive impulses and facilitate recovery from overdose, systemic disruption of endogenous opioid receptor signalling through the use of these antagonistic drugs can have severe side effects. In the light of these challenges, current efforts have focused on identifying new therapeutic targets that selectively and specifically modulate opioid receptor signalling and function so as to achieve analgesia without the adverse effects associated with chronic opiate use. We have previously reported that opioid receptors interact with each other to form heteromeric complexes and that these interactions affect morphine signalling. Since chronic morphine administration leads to an enhanced level of these heteromers, these opioid receptor heteromeric complexes represent novel therapeutic targets for the treatment of pain and opiate addiction. In this review, we discuss the role of heteromeric opioid receptor complexes with a focus on mu opioid receptor (MOR) and delta opioid receptor (DOR) heteromers. We also highlight the evidence for altered pharmacological properties of opioid ligands and changes in ligand function resulting from the heteromer formation.
Subject(s)
Analgesics , Morphine Dependence , Naloxone/therapeutic use , Naltrexone/therapeutic use , Narcotic Antagonists/therapeutic use , Protein Multimerization/drug effects , Receptors, Opioid, delta , Receptors, Opioid, mu , Analgesia , Animals , Drug Antagonism , Drug Overdose , Humans , Morphine Dependence/drug therapy , Morphine Dependence/metabolism , Naloxone/antagonists & inhibitors , Naltrexone/antagonists & inhibitors , Pain/drug therapy , Pain/metabolism , Protein Structure, Quaternary , Receptors, Opioid, delta/agonists , Receptors, Opioid, delta/antagonists & inhibitors , Receptors, Opioid, delta/metabolism , Receptors, Opioid, mu/agonists , Receptors, Opioid, mu/antagonists & inhibitors , Receptors, Opioid, mu/metabolism , Signal Transduction/drug effects , United StatesABSTRACT
The aims of the present study were to establish if nalfurafine, a kappa opioid agonist, inhibits compulsive scratching in mice elicited by the s.c. administration (behind the neck) of 5'-guanidinonaltrindole (GNTI), a kappa opioid antagonist; to assess if nalfurafine prevents c-fos expression provoked by GNTI or compound 48/80, two chemically diverse pruritogens; and to distinguish on the basis of neuroanatomy, those neurons in the brainstem activated by either GNTI-induced itch or formalin-induced pain (both compounds given s.c. to the right cheek). Pretreatment of mice with nalfurafine (0.001-0.03 mg/kg s.c.) attenuated GNTI (0.3 mg/kg)-evoked scratching dose-dependently. A standard antiscratch dose of nalfurafine (0.02 mg/kg) had no marked effect on the spontaneous locomotion of mice. Tolerance did not develop to the antiscratch activity of nalfurafine. Both GNTI and compound 48/80 provoked c-fos expression on the lateral side of the superficial layer of the dorsal horn of the cervical spinal cord and pretreating mice with nalfurafine inhibited c-fos expression induced by both pruritogens. In contrast to formalin, GNTI did not induce c-fos expression in the trigeminal nucleus suggesting that pain and itch sensations are projected differently along the sensory trigeminal pathway. Our data indicate that the kappa opioid system is involved, at least in part, in the pathogenesis of itch; and that nalfurafine attenuates excessive scratching and prevents scratch-induced neuronal activity at the spinal level. On the basis of our results, nalfurafine holds promise as a potentially useful antipruritic in human conditions involving itch.
Subject(s)
Antipruritics/pharmacology , Morphinans/pharmacology , Naltrexone/analogs & derivatives , Pruritus/drug therapy , Receptors, Opioid, kappa/agonists , Spiro Compounds/pharmacology , p-Methoxy-N-methylphenethylamine/antagonists & inhibitors , Afferent Pathways/drug effects , Afferent Pathways/metabolism , Afferent Pathways/physiopathology , Analgesics, Opioid/pharmacology , Analgesics, Opioid/therapeutic use , Animals , Antipruritics/therapeutic use , Biomarkers/analysis , Biomarkers/metabolism , Disease Models, Animal , Guanidines , Male , Mice , Morphinans/therapeutic use , Naltrexone/antagonists & inhibitors , Narcotic Antagonists/pharmacology , Nociceptors/drug effects , Nociceptors/metabolism , Pain Measurement , Posterior Horn Cells/cytology , Posterior Horn Cells/drug effects , Posterior Horn Cells/metabolism , Proto-Oncogene Proteins c-fos/drug effects , Proto-Oncogene Proteins c-fos/metabolism , Pruritus/chemically induced , Pruritus/physiopathology , Receptors, Opioid, kappa/antagonists & inhibitors , Receptors, Opioid, kappa/metabolism , Sensory Receptor Cells/drug effects , Sensory Receptor Cells/metabolism , Spinal Cord/drug effects , Spinal Cord/metabolism , Spinal Cord/physiopathology , Spiro Compounds/therapeutic use , Treatment OutcomeABSTRACT
The potent opioid [Dmt1]endomorphin-2 (Dmt-Pro-Phe-Phe-NH2) differentiated between the opioid receptor subtypes responsible for the antinociception elicited by endomorphin-2 in mice. Antinociception, induced by the intracerebroventricular administration of [Dmt1]endomorphin-2 and inhibited by various opioid receptor antagonists [naloxone, naltrindole, beta-funaltrexamine, naloxonazine], was determined by the tail-flick (spinal effect) and hot-plate (supraspinal effect) tests. The opioid receptor subtypes involved in [Dmt1]endomorphin-2-induced antinociception differed between these in vivo model paradigms: naloxone (non-specific opioid receptor antagonist) and beta-funaltrexamine (irreversible mu1/mu2-opioid receptor antagonist) blocked antinociception in both tests, although stronger inhibition occurred in the hot-plate than the tail-flick test suggesting involvement of other opioid receptors. Consequently, we applied naloxonazine (mu1-opioid receptor antagonist) that significantly blocked the effect in the hot-plate test and naltrindole (delta-opioid receptor antagonist), which was only effective in the tail-flick test. The data indicated that [Dmt1]endomorphin-2-induced spinal antinociception was primarily mediated by both mu2- and delta-opioid receptors, while a supraspinal mechanism involved only mu1/mu2-subtypes.
Subject(s)
Analgesia , Oligopeptides/pharmacology , Receptors, Opioid, delta/drug effects , Receptors, Opioid, mu/drug effects , Animals , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Hot Temperature/adverse effects , Injections, Intraventricular , Injections, Subcutaneous , Male , Mice , Naloxone/administration & dosage , Naloxone/analogs & derivatives , Naloxone/antagonists & inhibitors , Naloxone/pharmacokinetics , Naltrexone/administration & dosage , Naltrexone/analogs & derivatives , Naltrexone/antagonists & inhibitors , Naltrexone/pharmacokinetics , Nociceptors/drug effects , Oligopeptides/antagonists & inhibitors , Oligopeptides/chemical synthesis , Pain , Pain Measurement/drug effects , Pain Measurement/methods , Receptors, Opioid, delta/chemistry , Receptors, Opioid, delta/physiology , Receptors, Opioid, mu/physiology , Tail , Time FactorsABSTRACT
BACKGROUND: The mechanism by which the opioid antagonist naltrexone suppresses overconsumption of ethanol is unclear. Oral ethanol consumption in humans increases hypothalamic-pituitary-adrenal (HPA) activity, and recent studies suggest that naltrexone may reduce ethanol consumption by modifying the HPA-stimulating effects of ethanol. The purpose of this study was to measure in rhesus monkeys the effects of ethanol and naltrexone, alone and in combination, on plasma levels of adrenocorticotropin hormone (ACTH). METHODS: Nine adult male and female rhesus monkeys with chronic, indwelling intravenous catheters were maintained on tethers that allowed ethanol delivery and blood sampling. In one study, the monkeys received intramuscular injections of saline or 0.32 mg/kg naltrexone followed by noncontingent intravenous bolus infusions of saline or 0.3 to 1.8 g/kg ethanol. In a second study, other monkeys were given intramuscular injections of saline or 0.01 to 0.3 mg/kg naltrexone and subsequently responded on levers to receive intravenous saline or ethanol 0.03 g/kg per injection. RESULTS: Ethanol, delivered either response contingently or noncontingently, did not produce systematic changes in ACTH plasma levels. Naltrexone alone produced increases in plasma ACTH that were attenuated by the subsequent administration of noncontingent or response-contingent ethanol. Naltrexone also produced dose-dependent reductions in intravenous ethanol self-administration. Linear regression analysis indicated that ethanol intake was negatively correlated with the plasma levels of ACTH over time. CONCLUSIONS: The route of administration may modulate ethanol's effects on HPA activity. Ethanol may attenuate naltrexone's effect on the HPA axis by impairing HPA axis sensitivity to other stimuli. The negative correlation between ethanol intake and ACTH levels supports the notion that naltrexone's effect of increasing HPA axis activity may be related to its ability to suppress ethanol consumption.
Subject(s)
Ethanol/administration & dosage , Hypothalamo-Hypophyseal System/drug effects , Naltrexone/pharmacology , Pituitary-Adrenal System/drug effects , Adrenocorticotropic Hormone/blood , Alcohol Drinking/blood , Animals , Dose-Response Relationship, Drug , Female , Hypothalamo-Hypophyseal System/metabolism , Infusions, Intravenous , Macaca mulatta , Male , Naltrexone/antagonists & inhibitors , Pituitary-Adrenal System/metabolismABSTRACT
This study tested the hypothesis that stimulants (indirect dopamine agonists) attenuate the discriminative stimulus of naltrexone in monkeys chronically treated with L-alpha-acetylmethadol (LAAM). Four rhesus monkeys (Macaca mulatta) received LAAM (1.0 mg/kg s.c.) twice daily and discriminated a withdrawal-precipitating dose of naltrexone (0.0178 mg/kg s.c.) from saline. Cocaine (0.1-1.78 mg/kg), amphetamine (0.32-1.78 mg/kg), haloperidol (0.01-0.1 mg/kg), sulpiride (1.0-10.0 mg/kg), propranolol (0.32-3.2 mg/kg), clonidine (0.001-0.1 mg/kg), desipramine (0.32-3.2 mg/kg), and imipramine (1.0-10.0 mg/kg) were given s.c. before cumulative doses of naltrexone. Cocaine and amphetamine antagonized the discriminative stimulus effects of naltrexone, each shifting the naltrexone dose-effect curve significantly (e.g., 100-fold) rightward or downward. In contrast, the dopamine antagonist haloperidol shifted the naltrexone dose-effect curve 5-fold leftward. Sulpiride, desipramine, clonidine, and propranolol had comparatively less effect on the naltrexone discriminative stimulus, whereas some doses of imipramine attenuated the naltrexone stimulus in a manner similar to that of cocaine and amphetamine. These results support the notion that multiple neurotransmitter systems are involved in the discriminative stimulus effects of opioid withdrawal. Furthermore, these data are consistent with reports that dopamine levels decrease during opioid withdrawal and provide evidence that enhancing dopamine or other monoamine levels may attenuate subjective effects of opioid withdrawal.
Subject(s)
Amphetamine/pharmacology , Cocaine/pharmacology , Discrimination, Psychological/drug effects , Dopamine Uptake Inhibitors/pharmacology , Naltrexone/pharmacology , Opioid-Related Disorders , Animals , Discrimination, Psychological/physiology , Dose-Response Relationship, Drug , Female , Macaca mulatta , Male , Naltrexone/antagonists & inhibitors , Narcotic Antagonists/pharmacology , Opioid-Related Disorders/psychology , Substance Withdrawal Syndrome/psychologyABSTRACT
This case describes a heroin addict who was participating in a placebo-controlled randomized trial of naltrexone as an aid to relapse prevention. The patient tried to commit suicide by taking a heroin overdose after learning that he was HIV-positive. He was on naltrexone at the time and, as a result, survived what would probably have been a fatal overdose. This case demonstrates that naltrexone can have immediate as well as long-term positive effects in persons who are attempting to recover from heroin addiction.
Subject(s)
Heroin Dependence/psychology , Naltrexone/antagonists & inhibitors , Suicide Prevention , Adult , Drug Overdose/psychology , Humans , Male , Time FactorsABSTRACT
We examined the possibility that scratching induced by norbinaltorphimine, a selective kappa-opioid receptor antagonist, is due to an itch sensation, using compound 48/80 as control pruritogenic agent. When norbinaltorphimine was injected s.c. into the rostral back, mice scratched the skin around the injection site with their hind paws. Although the intensity of the scratching could not be compared because the dose and injection route were different, the character and time course of the scratching behavior induced by compound 48/80 injected i.d. were similar to those with norbinaltorphimine. The scratching behavior induced by norbinaltorphimine was dose-dependently and significantly inhibited by pretreatment with chlorpheniramine. Compound 48/80-induced scratching was also dose-dependently and significantly inhibited by p.o. pretreatment with chlorpheniramine. The scratching behavior induced by norbinaltorphimine was dose-dependently and significantly inhibited by pretreatment with U-50,488H (trans-(+/-)-2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] acetamide methansulfonate), a kappa-opioid receptor agonist. Unexpectedly, the scratching behavior induced by compound 48/80 was also dose-dependently and significantly reduced by pretreatment with U-50,488H. These results suggest that the injection of norbinaltorphimine into the rostral back of the mouse elicited scratching, which may be an itch-associated response. Furthermore, the scratching behavior produced by norbinaltorphimine may be due in part to the release of histamine followed by antagonism of kappa-opioid receptors.
Subject(s)
Behavior, Animal/drug effects , Naltrexone/pharmacology , Pruritus/chemically induced , Receptors, Opioid, kappa/antagonists & inhibitors , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/therapeutic use , Animals , Antipruritics/pharmacology , Antipruritics/therapeutic use , Chlorpheniramine/pharmacology , Chlorpheniramine/therapeutic use , Dose-Response Relationship, Drug , Histamine H1 Antagonists/pharmacology , Histamine H1 Antagonists/therapeutic use , Injections, Subcutaneous , Mice , Mice, Inbred ICR , Naltrexone/administration & dosage , Naltrexone/analogs & derivatives , Naltrexone/antagonists & inhibitors , Pruritus/drug therapy , Receptors, Opioid, kappa/agonists , Receptors, Opioid, kappa/metabolism , p-Methoxy-N-methylphenethylamine/pharmacologyABSTRACT
AIMS: To determine the kinetics of the formation of 6beta-naltrexol from naltrexone in human liver cytosol, and to investigate the role of potential inhibitors. METHODS: The kinetics of the formation of 6 beta-naltrexol from naltrexone were examined in eight human liver cytosol preparations using h.p.l.c. to quantify 6 beta-naltrexol and, the extent of inhibition of 6 beta-naltrexol formation was determined using chemical inhibitors. The formation of 6 beta-naltrexol and the back reaction of 6 beta-naltrexol to naltrexone were also examined in a microsomal preparation. RESULTS: The Vmax, Km and CLint values for the formation of 6 beta-naltrexol from naltrexone were in the ranges of 16-45 nmol mg-1 protein h-1, 17-53 microM and 0.3-2.2 ml h-1 mg-1 protein, respectively. The steroid hormones testosterone (Ki = 0.3 +/- 0.1 microM) and dihydrotestosterone (Ki = 0.7 +/- 0.4 microM) were the most potent competitive inhibitors of 6 beta-naltrexol formation, with naloxone, menadione and corticosterone also producing > 50% inhibition at a concentration of 100 microM. The opioid agonists morphine, oxycodone, oxymorphone and hydromorphone, and a range of benzodiazepines showed < 20% inhibition at 100 microM. In the microsomal preparation, there was no formation of naltrexone from 6beta-naltrexol nor any formation of 6beta-naltrexol from naltrexone. CONCLUSIONS: The intersubject variability in the kinetic parameters of 6beta-naltrexol formation could play a role in the efficacy of and patient compliance with naltrexone treatment. This variability could be due in part to a genetic polymorphism of the dihydrodiol dehydrogenase DD4, one of the enzymes reported to be responsible for the formation of 6beta-naltrexol from naltrexone. DD4 also has hydroxysteroid dehydrogenase activity which could account for the potent inhibition by the steroid hormones testosterone and dihydrotestosterone. The clinical significance of the latter finding remains to be established.
Subject(s)
Liver/metabolism , Naltrexone/analogs & derivatives , Naltrexone/metabolism , Adult , Aged , Analgesics, Opioid/pharmacology , Benzodiazepines/pharmacology , Chromatography, High Pressure Liquid , Corticosterone/pharmacology , Cytosol/drug effects , Cytosol/enzymology , Cytosol/metabolism , Dihydrotestosterone/pharmacology , Enzyme Inhibitors/pharmacology , Humans , Kinetics , Liver/drug effects , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Microsomes, Liver/metabolism , Middle Aged , Naloxone/pharmacology , Naltrexone/antagonists & inhibitors , Naltrexone/pharmacokinetics , Oxidoreductases/antagonists & inhibitors , Oxycodone , Reproducibility of Results , Substrate Specificity , Testosterone/pharmacology , Vitamin K/pharmacologyABSTRACT
RATIONALE: Patterns of competitive and insurmountable antagonism provide important data to guide the classification and characterization of different types of opioid agonists as well as infer the mechanism of action for agonists. OBJECTIVE: Experiments with the competitive antagonist, naltrexone, and the insurmountable antagonist, beta-funaltrexamine (beta-FNA), were conducted to determine whether the antinociceptive and rate-decreasing effects of the opioid agonists dezocine and d-propoxyphene are 1) mediated through muu opioid receptors in rats, and 2) differ from morphine with respect to relative efficacy. METHODS: The rat tail-withdrawal assay was used to measure antinociception and a fixed ratio 20 (FR20) schedule of food delivery was used to measure rate suppression. RESULTS: Naltrexone (0.01-1.0 mg/kg) was approximately equipotent as an antagonist of the antinociceptive and rate-decreasing effects of both morphine and dezocine and as an antagonist of the antinociceptive effects of d-propoxyphene. Naltrexone failed to block the rate-decreasing effects of d-propoxyphene. beta-FNA (5 and 10 mg/kg) also antagonized the antinociceptive and rate-decreasing effects of morphine and dezocine as well as the antinociceptive effects of d-propoxyphene. beta-FNA failed to produce a dose-dependent antagonism of the rate-decreasing effects of d-propoxyphene. CONCLUSIONS: These data suggest that the antinociceptive effects of morphine, dezocine, and d-propoxyphene and the rate-decreasing effects of morphine and dezocine are mediated through mu opioid receptors. Overall, high doses of beta-FNA produced a greater degree of antagonism of the behavioral effects of dezocine than morphine or d-propoxyphene, confirming other reports that dezocine is a lower efficacy agonist than morphine. Additionally, the degree of antagonism produced by beta-FNA was greater for the antinociceptive effects of all three compounds than for the rate-decreasing effects.
Subject(s)
Naltrexone/analogs & derivatives , Naltrexone/antagonists & inhibitors , Nociceptors/drug effects , Pain/physiopathology , Animals , Dose-Response Relationship, Drug , Male , RatsABSTRACT
Pharmacological, neurochemical and behavioural findings support a possible role of endogenous opioids in clinical depression. There is evidence from animal studies that delta-opioid receptors are involved in several behavioural responses to opioids, including motivational activities. In the present study, the mixed enkephalin catabolism inhibitor, RB 101 (N(R,S)-2-benzyl-3[(S)-(2-amino-4-methylthiobutyldithio]-1-oxoprop yl)-L-phenylalanine benzyl ester) (1.25, 2.5 and 5 mg/kg), induced a dose-dependent antidepressant-like effect in a learned helplessness model. Thus, RB 101 reversed escape deficits in rats previously subjected to inescapable shocks, suggesting the involvement of endogenous enkephalins in depression. Similar effects were observed after administration of the selective delta-opioid receptor agonist, BUBU (Tyr-D.Ser-(O-tert-butyl)-Gly-Phe-Leu-Thr(O-Tet-butyl-OH) (1 and 2 mg/kg). Moreover, RB 101 effects were antagonized by administration of naltrindole (NTI) (0.1 mg/kg), which points to a preferential involvement of delta-opioid receptors in this enkephalin-controlled behaviour. As RB 101 has been reported to be almost devoid of opiate-related side-effects, it could represent a promising alternative in the treatment of depressive patients who are unresponsive to, or intolerant of, classical antidepressants.
Subject(s)
Enkephalins/physiology , Helplessness, Learned , Receptors, Opioid, delta/physiology , Analgesics/pharmacology , Animals , Behavior, Animal/drug effects , Behavior, Animal/physiology , Disulfides/pharmacology , Drug Interactions , Male , Naltrexone/analogs & derivatives , Naltrexone/antagonists & inhibitors , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Oligopeptides/pharmacology , Phenylalanine/analogs & derivatives , Phenylalanine/pharmacology , Rats , Rats, Wistar , Receptors, Opioid, delta/agonists , Receptors, Opioid, delta/antagonists & inhibitorsABSTRACT
Single-unit recordings in anesthetized animals revealed that the L-type calcium channel antagonist, nimodipine (10 mg/kg), attenuated the activation of locus coeruleus neurons produced by naltrexone in opiate-dependent rats. Nimodipine also dose-dependently (1 mg/kg, 10 mg/kg, IP) inhibited the display of naloxone-precipitated withdrawal behaviors with a time course similar to that of nimodipine effects on the locus coeruleus. These data suggest that nimodipine may suppress opiate withdrawal via noradrenergic mechanisms.
Subject(s)
Calcium Channel Blockers/pharmacology , Locus Coeruleus/physiology , Morphine Dependence/psychology , Naltrexone/antagonists & inhibitors , Narcotic Antagonists/pharmacology , Nimodipine/pharmacology , Substance Withdrawal Syndrome/psychology , Animals , Dose-Response Relationship, Drug , Electrophysiology , Locus Coeruleus/drug effects , Male , Naltrexone/pharmacology , Norepinephrine/physiology , Rats , Rats, Sprague-DawleyABSTRACT
Chlornaltrexamine (beta-CNA, 0.5 micrograms) alone or beta-CNA plus either mu-agonist, D-Ala2-NMePhe4-Gly-ol-enkephalin (DAMGO, 500 ng) or delta-agonist, D-Pen2-D-Pen5-enkephalin (DPDPE, 10 micrograms) was injected intrathecally (i.t.) to protect mu- or delta-opioid receptors, respectively, for 24 h in male ICR mice. The antinociception was assessed by the tail-flick and hot-plate test. DPDPE or DAMGO injected i.t. increased inhibition of the tail-flick and hot-plate response in a dose-dependent manner. The dose-response curve for tail-flick and hot-plate response induced by DPDPE or DAMGO in i.t. saline-treated group significantly shifted to the right in i.t. beta-CNA alone treated group but returned to the control level in the group treated with i.t. beta-CNA coadministered with DPDPE or DAMGO, respectively. The effects of protection of mu- and delta-opioid receptor in the spinal cord on inhibition of the tail-flick and hot-plate response induced by beta-endorphin and morphine administered intracerebroventricularly (i.c.v.) were then studied. Intrathecal pretreatment with beta-CNA or beta-CNA coadministered with DAMGO attenuated inhibition of the tail-flick response induced by beta-endorphin administered i.c.v. However, i.t. treatment with beta-CNA coadministered with DPDPE did not affect inhibition of the tail-flick response induced by beta-endorphin administered i.c.v. Intrathecal pretreatment with beta-CNA or beta-CNA coadministered with either DPDPE or DAMGO did not alter inhibition of the hot-plate response induced by beta-endorphin administered i.c.v.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Analgesics/pharmacology , Enkephalins/pharmacology , Pain/physiopathology , Spinal Cord/drug effects , Amino Acid Sequence , Animals , Enkephalin, Ala(2)-MePhe(4)-Gly(5)- , Enkephalin, D-Penicillamine (2,5)- , Injections, Intraventricular , Injections, Spinal , Male , Mice , Mice, Inbred ICR , Molecular Sequence Data , Naltrexone/analogs & derivatives , Naltrexone/antagonists & inhibitors , Narcotic Antagonists/pharmacology , Pain Measurement/methods , beta-Endorphin/administration & dosageABSTRACT
The opioid antagonist effects of systemically administered nor-binaltorphimine (nor-BNI) were evaluated against the kappa agonists CI-977, U69,593, U50,488, ethylketocyclazocine (EKC), Mr2034 and bremazocine, the mu agonist morphine and the alkaloid delta agonist BW-373U86 in the acetic acid-induced writhing assay in mice. All eight agonists completely and dose-dependently inhibited writhing. Antagonism of CI-977 was apparent 1 h after administration of 32 mg/kg nor-BNI, peaking after 4 h and was maintained for at least 4 weeks; no antagonist effects of nor-BNI were apparent after 8 weeks. Nor-BNI (32 mg/kg) caused little or no antagonism of morphine or BW-373U86 at 1 h and none at 24 h after nor-BNI administration. Subsequently, dose-effect curves for CI-977, U50,488, U69,593, EKC, Mr2034 and bremazocine were determined 24 h after pretreatment with 3.2, 10 and 32 mg/kg nor-BNI. Pretreatment with 3.2 mg/kg nor-BNI produced significant antagonism of all six kappa agonists, suggesting that their antinociceptive effects were mediated at least in part by nor-BNI-sensitive kappa receptors. At higher doses, nor-BNI dose-dependently shifted the agonist dose-effect curves of CI-977, U50,488, U69,593 and bremazocine, but not those of EKC and Mr2034, suggesting that the latter compounds may be producing effects via nor-BNI-insensitive receptors. Mu receptor involvement was demonstrated following a 24 h pretreatment with 32 mg/kg beta-FNA in combination with nor-BNI, which significantly increased the degree of antagonism of Mr2034 and EKC from that seen with nor-BNI alone.2+ off
Subject(s)
Naltrexone/analogs & derivatives , Pain Measurement/drug effects , Receptors, Opioid, kappa/agonists , Animals , Dose-Response Relationship, Drug , Injections, Subcutaneous , Male , Mice , Naltrexone/antagonists & inhibitors , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Receptors, Opioid, kappa/antagonists & inhibitors , Receptors, Opioid, mu/antagonists & inhibitorsABSTRACT
The ability of the competitive opioid antagonist, naltrexone, to protect opioid receptors from inactivation by the nonequilibrium antagonists, beta-funaltrexamine (beta-FNA) and nor-binaltorphimine (nor-BNI), was examined in vivo. Male rats were injected SC with 10 mg/kg naltrexone or saline, 30 min before being injected intracisternally (IC) with water, 10 micrograms beta-FNA, or 1.0 or 10 micrograms nor-BNI. The rats were tested for analgesic responses to either U69,593 (nor-BNI groups) or morphine (beta-FNA groups), on a 50 degrees C hot plate, 24 h later. Morphine produced dose-related increases in the latency to paw lick in rats that received water (IC) (mean ED50 = 3.2 mg/kg). Little or no analgesia occurred after 1.0-30 mg/kg of morphine in animals that had received saline (SC) and 10 micrograms beta-FNA (IC) 24 h earlier. Pretreatment with 10 mg/kg naltrexone attenuated the antagonist effects of beta-FNA (morphine ED50 = 10.8 mg/kg). U69,593 also produced analgesia in animals that received water (IC) (ED50 = 0.97 mg/kg). This analgesia was dose-dependently blocked by nor-BNI for up to 7 days. Naltrexone did not inhibit the actions of nor-BNI. Thus, naltrexone prevented inactivation of mu receptors by beta-FNA but not inactivation of kappa receptors by nor-BNI, suggesting that antagonist interactions with mu receptors are different from those with kappa receptors.
Subject(s)
Benzeneacetamides , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Receptors, Opioid, kappa/antagonists & inhibitors , Receptors, Opioid, mu/antagonists & inhibitors , Analgesics/pharmacology , Animals , Cisterna Magna , Dose-Response Relationship, Drug , Injections , Male , Morphine/pharmacology , Naltrexone/antagonists & inhibitors , Pain Measurement/drug effects , Pyrrolidines/pharmacology , Rats , Rats, Sprague-DawleyABSTRACT
The effects of naltrindole, a selective delta-opioid receptor antagonist, on the capsaicin-induced cough reflex in mice and rats were studied. Intraperitoneal administration of naltrindole decreased the number of coughs both in mice and rats dose dependently. The cough-depressant effects reached a peak 15 min after the administration of naltrindole and lasted more than 120 min. Pretreatment with [D-Pen2,D-Pen5]enkephalin, a selective delta-opioid receptor agonist, partially but significantly reduced the antitussive effect of naltrindole. Blockade of kappa-opioid receptors by pretreatment with nor-binaltorphimine also partially antagonized the antitussive effect of naltrindole. However, the antitussive effect of naltrindole was not antagonized by beta-funaltrexamine, a selective mu-opioid receptor antagonist. Thus, it is possible that the antitussive effect of naltrindole may be mediated, in part, by kappa-opioid receptors. The present results provide evidence for the development of delta-opioid antagonists, especially naltrindole, for use as antitussive drugs.
Subject(s)
Antitussive Agents/pharmacology , Naltrexone/analogs & derivatives , Narcotic Antagonists/pharmacology , Receptors, Opioid, delta/antagonists & inhibitors , Animals , Capsaicin/antagonists & inhibitors , Capsaicin/pharmacology , Cough/chemically induced , Cough/prevention & control , Drug Interactions , Endorphins/pharmacology , Male , Mice , Mice, Inbred ICR , Naltrexone/antagonists & inhibitors , Naltrexone/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Opioid, kappa/antagonists & inhibitors , Receptors, Opioid, kappa/drug effectsABSTRACT
Buprenorphine produced a dose-dependent antagonism of the selective kappa opioid agonist U50,488 in squirrel monkeys responding under the shock titration procedure. In one group of four monkeys, 0.003-0.01 mg/kg buprenorphine produced dose-dependent rightward shifts in the individual U50,488 dose-effect curves and increased the A50 value for U50,488 more than 2-fold in each monkey. Furthermore, 0.01 mg/kg buprenorphine antagonized a maximally effective dose of U50,488 in these monkeys. Buprenorphine (0.01-0.1 mg/kg) also produced rightward shifts in the group U50,488 dose-effect curve for a second group of three monkeys. Buprenorphine's antagonism of U50,488 was probably not a consequence of any mu opioid antagonist properties of buprenorphine in this procedure since (1) buprenorphine produced an inconsistent antagonism of the selective mu agonist fentanyl, and (2) the selective mu antagonist beta-funaltrexamine did not antagonize U50,488. These results support the hypothesis that buprenorphine has kappa antagonist activity in the shock titration procedure.
Subject(s)
Analgesics/antagonists & inhibitors , Buprenorphine/pharmacology , Pyrrolidines/antagonists & inhibitors , Receptors, Opioid/drug effects , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer , Analgesics/administration & dosage , Animals , Electroshock , Fentanyl/administration & dosage , Fentanyl/antagonists & inhibitors , Male , Naltrexone/administration & dosage , Naltrexone/analogs & derivatives , Naltrexone/antagonists & inhibitors , Pyrrolidines/administration & dosage , Receptors, Opioid, kappa , SaimiriABSTRACT
White-tailed deer (Odocoileus virginianus) were immobilized with either 4.0 mg etorphine hydrochloride (ETOR) or 3.5 mg ETOR and 50.0 mg xylazine (XYL). Deer immobilized with ETOR only were given 4.0 mg nalmefene hydrochloride (NAL), a new opioid antagonist, 20 min after induction. Deer immobilized with ETOR and XYL received 3.5 mg NAL and 0.125 mg/kg yohimbine hydrochloride (YOH). The dose of 4.0 mg ETOR did not provide acceptable immobilization and was discontinued. A NAL:ETOR ratio of 1:1 was insufficient for complete and sustained antagonism of ETOR. Subsequently, deer were immobilized with ETOR and XYL as before which was then antagonized with 35.0 mg NAL and 0.125 mg/kg YOH. The 10:1 ratio of NAL:ETOR appeared to provide complete antagonism with no evidence of renarcotization. Although more study is required, NAL could become a useful antagonist for opioid-induced immobilizations.